Start typing to retrieve search suggestions. When suggestions are available use up and down arrows to review and ENTER to select. Continue typing to refine.
Advanced search

Report side effect

Report a suspected side effect or falsified product to the MHRA Yellow Card scheme.
Go to {yellow_card_logo} site
Trusted Information Creator
Certified November 2025
{arrow_up} Back to top

Ethosuximide Tillomed 250 mg Soft Capsules

{email} Notify me of changes to this product

emc account functionality

Sign in or register for an emc account to use this functionality and much more:

  • Get the latest updates to your inbox

    Receive email notifications when chosen products are updated

  • Stay up to date with document change history

    Get full access to document change history

  • Similar product search

    Use active ingredient, company or ATC code

  • Save your regular searches

    Simple access to search enquiries every time you need them

  • Favourite products you use most often

    Helps you find products you use regularly as fast as possible

Active Ingredient:
ATC code: 
N03AD01
{info_black}
About Medicine
{healthcare_pro_orange} This information is for use by healthcare professionals
Last updated on emc: 19 Nov 2026
1. Name of the medicinal product

Ethosuximide Tillomed 250 mg soft capsules

2. Qualitative and quantitative composition

Each soft capsule contains 250 mg ethosuximide.

Excipients with known effect: each soft capsule contains sorbitol 17.43 mg

For the full list of excipients see section 6.1.

3. Pharmaceutical form

Capsule, soft

Transparent clear, oblong, soft gelatin capsule filled with clear liquid. Imprinted with “HP 532” with white ink

4. Clinical particulars
4.1 Therapeutic indications

Ethosuximide Tillomed 250 mg soft capsules, give selective control of absence seizures (petit mal) even when complicated by grand mal.

It is also indicated for myoclonic seizures.

4.2 Posology and method of administration

Posology

Adults, Elderly and Children over 6 years

Start with a small dose - 500 mg daily with increments of 250 mg every five to seven days until control is achieved with 1000-1500 mg daily. Occasionally 2000 mg in divided doses may be necessary.

Children aged 0 to 6 years

Children aged 0-6 years old and those who are unable to swallow capsules should be given ethosuximide oral liquid.

Effective plasma levels of ethosuximide normally lie between 40 and 100 mcg per ml, but the clinical response should be the criteria for the regulation of the dosage. The half-life of ethosuximide in the plasma is more than 24 hours but the daily dose if large is more comfortably divided between morning and evening.

Currently available clinical trial data regarding the use of ethosuximide in the paediatric population are described in section 5.1.

The probability of dose-dependent undesirable effects can be reduced by careful dosing (small initial dose at the start of treatment, gradual increase of dose) and by taking the medicinal product during or after meals.

Anti-epileptic therapies are principally long-term therapies. A specialist (neurologist, neuropaediatrician) should decide about the start, duration and discontinuation of ethosuximide on an individual basis.

In general, reduction of the dose and discontinuation of the medicinal product should not be considered before the patient has been free from fits for 2-3 years.

The medicinal product must be discontinued by reducing the dose gradually over a period of one to two years.

Children may be allowed to outgrow the dose per kg body weight instead of adjusting the dose according to their age; however, it must be ensured that the EEC findings do not deteriorate.

Use with caution in hepatic or renal impairment. Monitor liver/renal function and ethosuximide concentrations.

Method of Administration

Ethosuximide Tillomed 250 mg soft capsules are for oral use.

The capsules can be taken during or after meals with some liquid.

4.3 Contraindications

• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Porphyrias

4.4 Special warnings and precautions for use

Suicidal Ideation and Behaviour

Suicidal ideation and behaviour have been reported in patients treated with anticonvulsants in several indications. A meta-analysis of randomised, placebo-controlled trials of Anti-Epileptic Drugs (AEDs) has also shown a small increased risk of suicidal ideation and behaviour. The mechanism of this risk is not known and the available data do not exclude the possibility of an increased risk for ethosuximide. Therefore, patients should be monitored for signs of suicidal ideation and behaviours and appropriate treatment should be considered. Patients (and caregivers of patients) should be advised to seek medical advice should signs of suicidal ideation or behaviour emerge.

All patients treated with AEDs should be routinely evaluated for depression and anxiety.

Ethosuximide, when used alone in mixed types of epilepsy, may increase the frequency of generalised tonic clonic (grand mal) seizures in some patients.

As with other anticonvulsants, it is important to proceed slowly when increasing or decreasing dosage, as well as when adding or eliminating other medication. Abrupt withdrawal of anticonvulsant medication may precipitate absence (petit mal) seizures.

Haemopoietic Effect

Special attention should be given to clinical symptoms of bone marrow damage (fever, angina, haemorrhage) (see section 4.8). It is recommended to check the blood count regularly (initially monthly, after one year every six months) to identify potential bone marrow damage. At a leucocyte count of less than 3500/mm3 or a granulocyte ratio of less than 25%, the dose should be reduced or the therapy discontinued. The liver enzymes should also be checked regularly.

Hepatic/Renal Impairment

Ethosuximide should be used with extreme caution in patients with impaired hepatic or renal function.

Periodic urinalysis and liver function studies are advised for all patients receiving the drug. Ethosuximide is capable of producing morphological and functional changes in the animal liver. In humans, abnormal liver and renal function studies have been reported.

Autoimmune Disorders

Cases of systemic lupus erythematosus have been reported with the use of ethosuximide. The physician should be alert to this possibility. Additionally, lupus-like reactions have been reported in children given ethosuximide. They vary in severity from systemic immunological disorders, which include the nephrotic syndrome, to the asymptomatic presence of antinuclear antibodies. The nephrotic syndrome is rare and a complete recovery has usually been reported on drug withdrawal.

Severe Cutaneous Adverse Reactions (SCARs)

Hypersensitivity Syndrome (HSS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Hypersensitivity Syndrome (HSS) or Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking anticonvulsant drugs, including ethosuximide. Some of these events have been fatal or life threatening.

HSS/DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, haematological abnormalities, myocarditis, myositis or pneumonitis. Initial symptoms may resemble an acute viral infection. Other common manifestations include arthralgias, jaundice, hepatomegaly, leucocytosis, and eosinophilia. The interval between the first drug exposure and symptoms is usually 2 to 4 weeks but has been reported in individuals receiving anticonvulsants for 3 or more months. If such signs and symptoms occur, the patient should be evaluated immediately.

Ethosuximide should be discontinued if an alternative aetiology for the signs and symptoms cannot be established.

Patients at higher risk for developing HSS/DRESS include black patients, patients who have experienced this syndrome in the past (with ethosuximide or other anticonvulsant drugs), patients who have a family history of this syndrome and immuno-suppressed patients. The syndrome is more severe in previously sensitised individuals.

Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)

Life-threatening cutaneous reactions Stevens-Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN) have been reported with the use of ethosuximide. Although serious skin reactions may occur without warning, patients should be advised of the signs and symptoms of HSS/DRESS (see section 4.4), occurrence of rash and should be monitored closely for skin reactions. Patients should seek medical advice from their physician immediately when observing any indicative signs or symptoms. The highest risk for occurrence of SJS or TEN is within the first weeks of treatment.

If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) are present, ethosuximide treatment should be discontinued. The best results in managing SJS and TEN come from early diagnosis and immediate discontinuation of any suspect drug. Early withdrawal is associated with a better prognosis. If the patient has developed SJS or TEN with the use of ethosuximide, ethosuximide must not be re-started in this patient at any time.

If the rash is of a milder type (measles-like or scarlatiniform), therapy may be resumed after the rash has completely disappeared. If the rash recurs upon reinstitution of therapy, further ethosuximide medication is contraindicated. The risk of serious skin reactions and other hypersensitivity reactions to ethosuximide may be higher in black patients.

Studies in patients of Chinese ancestry have found a strong association between the risk of developing SJS/TEN and the presence of human leukocyte antigen HLA-B*1502, an inherited allelic variant of the HLA-B gene, in patients using carbamazepine. HLA-B*1502 may be associated with increased risk of developing SJS/TEN in patients of Thai and Han Chinese ancestry taking drugs associated with SJS/TEN, including ethosuximide. If these patients are known to be positive for HLA-B*1502, the use of ethosuximide should only be considered if the benefits are thought to exceed the risks.

In the Caucasian and Japanese population, the frequency of HLA-B*1502 allele is extremely low, and thus it is not possible at present to conclude on risk association. Adequate information about risk association in other ethnicities is currently not available.

Information for Patients

Patients taking ethosuximide should be advised of the importance of adhering strictly to the prescribed dosage regimen.

Patients should be instructed to promptly contact their physician if they develop signs and/or symptoms (e.g. sore throat, fever) suggesting an infection.

Withdrawal

If ethosuximide is being substituted for another anti-epileptic drug the latter must not be withdrawn abruptly but the replacement made gradually with overlap of the preparations otherwise petit mal may break through.

Ethosuximide should always be withdrawn slowly.

Excipients

This medicine contains 17.43 mg sorbitol per capsule.

The additive effect of concomitantly administered products containing sorbitol (or fructose) and dietary intake of sorbitol (or fructose) should be taken into account.

The content of sorbitol in medicinal products for oral use may affect the bioavailability of other medicinal products for oral use administered concomitantly. Patients with hereditary fructose intolerance (HFI) should not take/be given this medicinal product.

4.5 Interaction with other medicinal products and other forms of interaction

If ethosuximide is administered in combination with other anticonvulsants, the dosage of ethosuximide and/or other anticonvulsants should be adjusted, depending on the patient's response. Ethosuximide interacts with other anticonvulsants such as phenytoin and valproic acid. It is recommended that serum concentrations of the individual substances be regularly determined.

The plasma concentrations of ethosuximide may be reduced by carbamazepine, primidone, phenobarbital and lamotrigine and increased by isoniazid.

Concomitant use of ethosuximide and alcohol or substances with sedative properties should be avoided in order to prevent CNS depression.

4.6 Fertility, pregnancy and lactation

Women of childbearing potential

Women of childbearing potential should be advised by their doctor of the necessity of planning and monitoring a pregnancy before starting the treatment with ethosuximide. Patients should be advised to tell their doctor immediately if they have become pregnant during the treatment. The prescribing physician should weigh the benefit versus risk of ethosuximide in treating or counselling epileptic women of childbearing potential.

Pregnancy

Ethosuximide crosses the placenta. Reports suggest an association between the use of other anticonvulsant drugs by women with epilepsy and an elevated incidence of birth defects in children born to those women. Cases of birth defects have been reported with ethosuximide.

The likelihood of harmful effects occurring in the unborn foetus appears to be greater in combination with other anticonvulsant agents.

In general, it is not desirable to discontinue anticonvulsant therapy during pregnancy. Where possible, preference should be given to monotherapy during pregnancy. The lowest, yet still effective, ethosuximide doses must be given and plasma concentrations must be monitored.

Some anticonvulsant agents may cause folic acid deficiency. Moreover, folic acid supplementation - at doses customary for all pregnant women - is strongly recommended. To avoid bleeding complications in the newborn infant due to possible vitamin K deficiency, which has been reported after maternal use of some anticonvulsant agents, consideration can be given to administering vitamin K to the mother in the last weeks of pregnancy. For the newborn infant, parenteral administration of vitamin K is advised immediately postpartum.

The prescribing physician should weigh the benefit versus risk of ethosuximide in treating or counselling epileptic women of childbearing potential.

Breast-feeding

Ethosuximide is excreted in breast milk.

Because the effects of ethosuximide on the nursing infant are unknown, caution should be exercised when ethosuximide is administered to a nursing mother. Ethosuximide should be used in nursing mothers only if the benefits clearly outweigh the risks.

Breast-feeding is not recommended during treatment with ethosuximide.

Fertility

There are no data on the effects of Ethosuximide 250 mg capsules, soft on male or female fertility.

4.7 Effects on ability to drive and use machines

Ethosuximide may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving or other such activities requiring alertness. Therefore, the patient should be cautioned accordingly.

4.8 Undesirable effects

The frequency of possible undesirable effects is defined using the following convention:

Very common (≥ 1/10)

Common (≥ 1/100 to < 1/10)

Uncommon (> 1/1,000 to < 1/100)

Rare (> 1/10,000 to < 1/1000)

Very rare (<1/10,000)

Not known (frequency cannot be estimated from the available data).

* AE frequency estimated from post-marketing safety database

MedDRA System Organ Class

Frequency

Undesirable Effects

Blood and lymphatic system disorders

Uncommon

Aplastic anaemia*, agranulocytosis*, pancytopenia*, eosinophilia*, leukopenia*, bone marrow failure

Not known

Thrombocytopenia

Immune system disorders

Uncommon

Hypersensitivity*

Metabolism and nutrition disorders

Common

Decreased appetite

Psychiatric disorders

Uncommon

Aggression*, sleep terror*, depression*, suicidal ideation*, psychotic disorder*, sleep disorder*

Not known

Euphoric mood, apathy, increased libido

Nervous system disorders

Common

Ataxia, headache#, dizziness#, drowsiness

Uncommon

Psychomotor hyperactivity*, lethargy, disturbance in attention*

Not known

Extrapyramidal side effects, increased frequency of grand mal convulsions

Eye disorders

Uncommon

Myopia*

Respiratory, thoracic and mediastinal disorders

Uncommon

Hiccups

Gastrointestinal disorders

Common

Abdominal pain, abdominal pain upper, gastrointestinal disorder, nausea#, vomiting#, abdominal discomfort

Uncommon

Diarrhoea, gum hypertrophy*, swelling of the tongue*

Skin and subcutaneous tissue disorders

Common

Rash erythematous, urticaria

Uncommon

Stevens-Johnson syndrome*

Not known

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

Musculoskeletal and connective tissue disorders

Uncommon

Systemic Lupus Erythematosus (SLE) *

Renal and urinary disorders

Uncommon

Haematuria*

Reproductive system and breast disorders

Uncommon

Vaginal bleeding*

General disorders and administration site conditions

Uncommon

Fatigue, irritability*

Investigations

Uncommon

Weight loss

#In combined forms of epilepsy and also in combination with other anticonvulsant agents, 20- 30% experienced nausea, vomiting, headache, dizziness.

In most cases of leucopenia the blood picture has returned to normal on reduction of dose or discontinuation. In some instances, patients who become leucopenic on other anticonvulsant therapy have been satisfactorily treated with ethosuximide alone.

Patients should be advised to seek immediate medical attention for full blood count tests if symptoms such as fever, sore throat, mouth ulcers, bruising or bleeding develop.

Ethosuximide when used alone in mixed types of epilepsy may increase the frequency of generalised tonic-clonic (grand mal) seizures in some patients.

Psychotic states thought to be induced or exacerbated by anticonvulsant therapy have been reported.

Lupus like reactions have occasionally been reported in children given ethosuximide, varying from severe systemic immunological disorders, e.g. the nephrotic syndrome generally with complete recovery on drug withdrawal, to the detection of antinuclear antibodies without clinical features.

Summary of safety profile

Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS) and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) have been reported in association with ethosuximide treatment (see section 4.4). As a rule, adverse reactions resolve when the dosage is reduced. Usually, they do not recur upon subsequent dose escalation.

Psychiatric or psychological aberrations associated with ethosuximide administration may be noted particularly in patients who have previously exhibited psychological abnormalities.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms

Acute overdoses may produce nausea, vomiting and CNS depression including coma and respiratory depression. Due to the long half-life, effects can persist for a long time.

Management

If less than 2 g have been taken, fluids should be given by mouth. If a larger dose has been taken the stomach should be emptied, respiration maintained and any other symptoms treated accordingly. Absorption may be prevented by inducing emesis or gastric lavage, followed by administration of activated charcoal (adsorbent) and sodium sulphate (laxative). Intensive care admission is indicated. Haemodialysis may be useful. Forced diuresis and exchange transfusions are ineffective.

5. Pharmacological properties
5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Anticonvulsants, ATC code: N03AD01.

Ethosuximide is a succinimide derivative.

Mechanism of action

The reduction of seizure frequency is thought to be achieved by depression of the motor cortex and elevation of the threshold to convulsive stimuli as seen by the suppression of the characteristic spike and wave EEG pattern.

Pharmacodynamic effects

Ethosuximide gives selective control of absence seizures (petit mal) even when complicated by grand mal. It is also indicated for myoclonic seizures. Compared to other anti-convulsants, ethosuximide is more specific for pure petit mal.

Paediatric population

In a double-blind, randomised trial of 20 weeks duration in 453 children aged 2.5 to 13 years old with newly diagnosed childhood absence epilepsy, the efficacy, tolerability and neuropsychological effects of ethosuximide, valproic acid and lamotrigine as monotherapy in childhood absence epilepsy were investigated. Those treated with either ethosuximide or valproic acid had higher freedom from failure rates (53% and 58%, respectively) than those given lamotrigine (29%; odds ratio with ethosuximide vs. lamotrigine, 2.66; 95% confidence interval [CI], 1.65 to 4.28; odds ratio with valproic acid vs. lamotrigine, 3.34; 95% CI, 2.06 to 5.42; P<0.001 for both comparisons). In both pre-specified and post-hoc analyses, ethosuximide resulted in fewer attentional effects as compared with valproic acid (at week 16 and week 20, the percentage of subjects with a Confidence Index score of 0.60 or higher in the Conners' Continuous Performance Test was greater in the valproic acid group than in the ethosuximide group [49% vs. 33%; odds ratio, 1.95; 95% CI, 1.12 to 3.41; P = 0.03] and the lamotrigine group [49% vs. 24%; odds ratio, 3.04; 95% CI, 1.69 to 5.49; P <0.001]).

5.2 Pharmacokinetic properties

Absorption

Ethosuximide is readily absorbed from the gastro-intestinal tract and extensively metabolised in the liver.

Distribution

It is widely distributed throughout the body but is not significantly bound to plasma proteins so saliva concentrations may be useful for monitoring.

Peak serum levels occur 1 to 7 hours after single oral dose. Therapeutic levels are between 40 and 100 mcg/ml. It has a long elimination half-life: adults 40 - 60 hours; children 30 hours.

Elimination

It is excreted in the urine mainly in the form of its metabolites.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of acute and repeated dose toxicity.

Ethosuximide did not reveal a potential for mutagenicity or chromosome aberrations when studied in vitro.

Long-term studies of the carcinogenic potential in animals have not been performed.

Embryotoxicity studies in rats and mice revealed a higher incidence rate of malformation and changes in behaviour.

The results of the pre-clinical tests do not add anything of further significance to the prescriber.

6. Pharmaceutical particulars
6.1 List of excipients

Gelatin

Glycerol

Sorbitol (E420)

Macrogol 400

Purified Water

 

Printing ink:

Shellac Glaze ~45% (E904)

Titanium Dioxide (E171)

Isopropyl Alcohol

Propylene Glycol (E1520)

N-Butyl Alcohol

Ammonium Hydroxide 28% (E527)

Simethicone

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months

6.4 Special precautions for storage

This medicinal product does not require any special storage conditions.

6.5 Nature and contents of container

- HDPE bottle pack with white, round, plastic (polypropylene) child-resistant closure cap with liner.

   Pack sizes: 56, 100, 200 capsules

- PVC/PVDC/Alu blister pack in carton.

   Pack size: 56 capsules

Not all pack types or sizes may be marketed.

6.6 Special precautions for disposal and other handling

No special requirements.

7. Marketing authorisation holder

Tillomed Laboratories Limited

220 Butterfield

Great Marlings

Luton

LU2 8DL

United Kingdom

8. Marketing authorisation number(s)

PL 11311/0682

9. Date of first authorisation/renewal of the authorisation

19/01/2024

10. Date of revision of the text

11/11/2026

Tillomed Laboratories Ltd
Company image
Address
220 Butterfield, Great Marlings, Luton, LU2 8DL, UK
Telephone
+44 (0)1480 402 400
Medical Information Direct Line
+44 (0)1480 402 400 [option 2]
Medical Information e-mail
[email protected]
Customer Care direct line
+44 (0)1480 402 400 [option 1]
Stock Availability
+44 (0)1480 402 400 [option 1]